BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company believes new data strengthen the case for...
BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BC Innovations | Nov 19, 2019
Distillery Therapeutics

AGR2 and LYPD3 as breast cancer targets

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Inhibiting the membrane receptor LYPD3 or its ligand AGR2 could treat endocrine therapy-resistant breast cancer. In patients with estrogen receptor-positive breast cancer, higher tumor levels of LYPD3 protein were...
BC Extra | Oct 17, 2019
Clinical News

Syros prioritizing oral CDK7, dropping IV after Phase I data

After tolerability issues in a Phase I trial led to lower doses and longer infusion times for its first clinical CDK7 inhibitor, Syros is choosing to concentrate instead on a preclinical oral compound aimed at...
BC Extra | Sep 30, 2019
Clinical News

Phase II data for G1’s trilaciclib raises questions about its uptake potential in TNBC

G1 showed trilaciclib led to a significant reduction in the risk of death for metastatic triple-negative breast cancer, but a shifting treatment landscape that includes checkpoint inhibitors could mean an uncertain commercial and regulatory path...
BC Extra | Jul 31, 2019
Clinical News

July 31 Clinical Quick Takes: Novartis' Kisqali shows OS benefit; plus Atlantic and Translate Bio

Kisqali improves survival for postmenopausal breast cancer  Novartis AG (NYSE:NVS; SIX:NOVN) reported interim data showing CDK4/CDK6 inhibitor Kisqali ribociclib plus fulvestrant met the secondary endpoint of significantly improved overall survival in the Phase III MONALEESA-3...
BC Extra | Jul 31, 2019
Clinical News

July 30 Clinical Quick Takes: Biogen, Alkermes MS candidate superior to Tecfidera; plus Amgen, Lilly and more

Biogen, Alkermes Phase III MS candidate beats Tecfidera  Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) said diroximel fumarate (BIIB098) met the primary endpoint in the Phase III EVOLVE-MS-2 trial: superiority to Biogen’s Tecfidera dimethyl fumarate...
BC Extra | Jun 24, 2019
Politics & Policy

June 24 P&P Quick Takes: Priority generics in China; plus CMS price transparency and more

China publishes list of generic drugs for priority approval  To encourage development of generic drugs, China’s National Health Commission (NHC) announced the country's first annual list of 34 off-patent and soon to be off-patent drugs,...
BC Extra | Jun 3, 2019
Clinical News

June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more

Celgene highlights iberdomide data for MM at ASCO  Celgene Corp. (NASDAQ:CELG) presented data at ASCO Sunday showing that iberdomide (CC-220) plus dexamethasone led to an overall response rate (ORR) of 32%, including 17 partial responses...
BC Extra | May 24, 2019
Company News

Novartis breast cancer drug marks first approval of PI3Kα inhibitor

Piqray alpelisib became the first FDA-approved PI3Kα inhibitor on Friday, as well as the first novel drug approved under the agency's Real-Time Oncology Review pilot program. FDA approved the breast cancer drug about three months...
Items per page:
1 - 10 of 117